SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ind-Swift gets renewed approval for Global Business Unit

30 May 2025 Evaluate

Ind-Swift has received renewed approval for its 100% Export Oriented Unit (Global Business Unit (GBU)) situated at Punjab for a period of three years from Medicines & Healthcare Products Regulatory Agency (MHRA), London, United Kingdom. The approval is based on the assessment undertaken by the agency of company’s quality metrics and quality systems.

Ind-Swift is Chandigarh based pharmaceutical company, established in 1986 with a mission of winning global customers through innovative pharmaceutical products.

Ind-Swift - Amalgama Share Price

15.70 0.00 (0.00%)
13-Aug-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1834.40
Dr. Reddys Lab 1306.80
Cipla 1362.85
Zydus Lifesciences 940.10
Lupin 2459.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×